Table 3 RASIs (ACEIs and ARBs) used in the study groups
From: Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer
Group | Drug | n(%) |
|---|---|---|
ACEI | ramipril | 49 (39.8) |
enalapril | 28 (22.8) | |
perindopril | 16 (13.0) | |
cilazapril | 8 (6.5) | |
lisinopril | 8 (6.5) | |
ramipril | 5 (4.1) | |
quinapril | 4 (3.3) | |
trandolapril | 3 (2.4) | |
imidapril | 1 (0.8) | |
zofenopril | 1 (0.8) | |
ARB | losartan | 18 (51.4) |
valsartan | 11 (31.4) | |
telmisartan | 6 (17.2) |